Top NASDAQ Biotech Stocks : VIVUS, GERN, SHPGY

Subscribe to FREE Stock Market News Alerts by visiting: http://www.PennyStockPickReport.com

VIVUS, Inc. (NASDAQ:VVUS) climbed 4.52% over its previous day’s price and now trades at $8.13 on a massive volume of 2.79 million shares. Yesterday it announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C.  Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009. Top-line results from the phase 3 studies were previously reported in September 2009.  The presentation included data from the EQUIP (OB-302) and CONQUER (OB-303) studies that further supports the safety and efficacy profile of Qnexa.

Geron Corporation (NASDAQ:GERN) is amongst the top gainer in the early morning trade and soared 8.67% to $6.27 on huge volume of 888k shares. The company reported financial results for the three and nine months ended September 30, 2009. For the third quarter of 2009, the company reported net loss applicable to common stockholders of $15.2 million, or $(0.17) per share, compared to $17.2 million, or $(0.22) per share, for the comparable 2008 period. Net loss applicable to common stockholders for the first nine months of 2009 was $52.0 million, or $(0.59) per share, compared to $44.4 million, or $(0.57) per share, for the comparable 2008 period. Revenues for the third quarter of 2009 were $494,000, compared to $367,000 for the comparable 2008 period. Revenues for the first nine months of 2009 were $1.1 million, compared to $2.3 million for the comparable 2008 period.

Shire Plc. (ADR) (NASDAQ:SHPGY) is amongst the top gainers in the early hour of the opening trade. The stock has spurted 4.78% and is trading at $53.53 with a huge volume of 699K shares. Today the company reiterated its fiscal 2009 outlook and expects non GAAP diluted earnings per ADS (EPS) in the range of $3.00-$3.40. The stock has a 52-week range of $31.66-$54.06.  Today the stock also created a new 52-week high at $54.06.